Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IL15-TransDC |
Synonyms | |
Therapy Description |
IL15-TransDC comprises WT1-targeted dendritic cells engineered to transpresent IL-15, which potentially induce activation of CD8+ T-lymphocytes and increase antitumor immune response (PMID: 28785596). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IL15-TransDC | IL15-TransDC comprises WT1-targeted dendritic cells engineered to transpresent IL-15, which potentially induce activation of CD8+ T-lymphocytes and increase antitumor immune response (PMID: 28785596). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05964361 | Phase Ib/II | IL15-TransDC | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients | Recruiting | BEL | 0 |